Vega-Diaz Nicanor, Gonzalez-Cabrera Fayna, Marrero-Robayna Silvia, Santana-Estupiñan Raquel, Gallego-Samper Roberto, Henriquez-Palop Fernando, Perez-Borges Patricia, Rodriguez-Perez José Carlos
Nephrology Service, Hospital Universitario de Gran Canaria Dr. Negrin, Universidad de Las Palmas de Gran Canaria, 35019 Las Palmas de Gran Canaria, Spain.
J Clin Med. 2015 Jul 22;4(7):1518-35. doi: 10.3390/jcm4071518.
In order to reduce the cardiovascular risk, morbidity and mortality of peritoneal dialysis (PD), a minimal level of small-solute clearances as well as a sodium and water balance are needed. The peritoneal dialysis solutions used in combination have reduced the complications and allow for a long-time function of the peritoneal membrane, and the preservation of residual renal function (RRF) in patients on peritoneal dialysis (PD) is crucial for the maintenance of life quality and long-term survival. This retrospective cohort study reviews our experience in automatic peritoneal dialysis (APD) patients, with end-stage renal disease (ESRD) secondary to diabetic nephropathy (DN) in comparison to non-diabetic nephropathy (NDN), using different PD solutions in combination.
Fifty-two patients, 29 diabetic and 23 non-diabetic, were included. The follow-up period was 24 months, thus serving as their own control.
The fraction of renal urea clearance (Kt) relative to distribution volume (V) (or total body water) (Kt/V), or creatinine clearance relative to the total Kt/V or creatinine clearance (CrCl) decreases according to loss of RRF. The loss of the slope of RRF is more pronounced in DN than in NDN patients, especially at baseline time interval to 12 months (loss of 0.29 mL/month vs. 0.13 mL/month, respectively), and is attenuated in the range from 12 to 24 months (loss of 0.13 mL/month vs. 0.09 mL/month, respectively). Diabetic patients also experienced a greater decrease in urine output compared to non-diabetic, starting from a higher baseline urine output. The net water balance was adequate in both groups during the follow up period. Regarding the balance sodium, no inter-group differences in sodium excretion over follow up period was observed. In addition, the removal of sodium in the urine output decreases with loss of renal function. The average concentration of glucose increase in the cycler in both groups (DN: baseline 1.44 ± 0.22, 12 months 1.63 ± 0.39, 24 months 1.73 ± 0.47; NDN: baseline 1.59 ± 0.40, 12 months 1.76 ± 0.47, 24 months 1.80 ± 0.46), in order to maintain the net water balance. The daytime dwell contribution, the fraction of day and the renal fraction of studies parameters provide sustained benefit in the follow-up time, above 30%.
The wet day and residual renal function are determinants in the achievement of the objective dose of dialysis, as well as in the water and sodium balance. The cause of chronic kidney disease (CKD) does not seem to influence the cleansing effectiveness of the technique.
为降低腹膜透析(PD)患者的心血管风险、发病率和死亡率,需要维持最低水平的小分子溶质清除率以及钠水平衡。联合使用的腹膜透析液减少了并发症的发生,并使腹膜长期发挥功能,而保留腹膜透析(PD)患者的残余肾功能(RRF)对于维持生活质量和长期生存至关重要。本回顾性队列研究回顾了我们在自动腹膜透析(APD)患者中的经验,这些患者患有糖尿病肾病(DN)继发的终末期肾病(ESRD),并与非糖尿病肾病(NDN)患者进行比较,采用了不同的联合腹膜透析液。
纳入52例患者,其中29例为糖尿病患者,23例为非糖尿病患者。随访期为24个月,并以患者自身作为对照。
相对于分布容积(V)(或总体水)的肾尿素清除率分数(Kt)(即Kt/V),或相对于总Kt/V或肌酐清除率(CrCl)的肌酐清除率,会随着RRF的丧失而降低。DN患者RRF斜率的丧失比NDN患者更明显,尤其是在基线至12个月期间(分别为每月丧失0.29 mL vs. 0.13 mL),而在12至24个月期间有所减缓(分别为每月丧失0.13 mL vs. 0.09 mL)。与非糖尿病患者相比,糖尿病患者的尿量从更高的基线水平开始下降幅度更大。随访期间两组的净水平衡均充足。关于钠平衡,随访期间未观察到组间钠排泄的差异。此外,随着肾功能丧失,尿钠排泄量减少。为维持净水平衡,两组循环器中葡萄糖的平均浓度均升高(DN组:基线时1.44±0.22,12个月时1.63±0.39,24个月时1.73±0.47;NDN组:基线时1.59±0.40,12个月时1.76±0.47,24个月时1.80±0.46)。日间留腹时间、日间占比以及研究参数的肾部分占比在随访期间提供了超过30%的持续益处。
湿日和残余肾功能是实现目标透析剂量以及维持水和钠平衡的决定因素。慢性肾脏病(CKD)的病因似乎并不影响该技术的清除效果。